A MD Anderson Cancer Center preliminary study published in the Journal of Pain and Symptom Management found that advanced cancer patients who were treated with cranial electrotherapy stimulation (CES) via a handheld, noninvasive medical device called Alpha-Stim for 4 weeks saw significant improvement of pain, anxiety, and depression, with insomnia relief trending toward significant.
While Alpha-Stim is FDA cleared, there have yet to be published studies in patients with advanced cancer. This study examined the safety and efficacy of this non-drug treatment option.
Jeffrey Marksberry, MD, chief science and clinical officer at Electromedical Products International Inc (EPI), which makes the Alpha-Stim, says in a release, “We are very proud and excited about this independent study from MD Anderson. It further corroborates the previous independent studies that found that Alpha-Stim is a viable treatment option for pain, anxiety, insomnia and depression, even in one of the most difficult-to-treat patient populations,” Marksberry said. “Not only is it viable, but it is also faster, safer and more effective than pharmaceuticals, without the addictive qualities, and in the long run less expensive.”
